<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR316.html">Part 316
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 316.14  Refusal to provide written recommendations.
                            </h3>
                            <p class="depth1"><em>(a)</em> FDA may refuse to provide written recommendations concerning the   nonclinical laboratory studies and clinical investigations necessary for  approval of a marketing application for any of the following reasons:</p><p class="depth2"><em>(1)</em> The information required to be submitted by Sec. 316.10(b) has  not been submitted, or the information submitted is incomplete.</p><p class="depth2"><em>(2)</em> There is insufficient information about:</p><p class="depth3"><em>(i)</em> The drug to identify the active moiety and its physical and  chemical properties, if these characteristics can be determined; or</p><p class="depth3"><em>(ii)</em> The disease or condition to determine that the disease or  condition is rare in the United States; or</p><p class="depth3"><em>(iii)</em> The reasons for believing that the drug may be useful for  treating the rare disease or condition with that drug; or</p><p class="depth3"><em>(iv)</em> The regulatory and marketing history of the drug to determine  the scope and type of investigations that have already been conducted on  the drug for the rare disease or condition; or</p><p class="depth3"><em>(v)</em> The plan of study for establishing the safety and effectiveness  of the drug for treatment of the rare disease or condition.</p><p class="depth2"><em>(3)</em> The specific questions for which the sponsor seeks the advice of  the agency are unclear or are not sufficiently specific.</p><p class="depth2"><em>(4)</em> On the basis of the information submitted and on other  information available to the agency, FDA determines that the disease or  condition for which the drug is intended is not rare in the United  States.</p><p class="depth2"><em>(5)</em> On the basis of the information submitted and on other  information available to the agency, FDA determines that there is an  inadequate basis for permitting investigational use of the drug under  part 312 of this chapter for the rare disease or condition.</p><p class="depth2"><em>(6)</em> The request for information contains an untrue statement of  material fact.</p><p class="depth1"><em>(b)</em> A refusal to provide written recommendations will be in writing  and will include a statement of the reason for FDA's refusal. Where  practicable, FDA will describe the information or material it requires  or the conditions the sponsor must meet for FDA to provide  recommendations.</p><p class="depth1"><em>(c)</em> Within 90 days after the date of a letter from FDA requesting  additional information or material or setting forth the conditions that  the sponsor is asked to meet, the sponsor shall either:</p><p class="depth2"><em>(1)</em> Provide the information or material or amend the request for  written recommendations to meet the conditions sought by FDA; or</p><p class="depth2"><em>(2)</em> Withdraw the request for written recommendations. FDA will  consider a sponsor's failure to respond within 90 days to an FDA letter  requesting information or material or setting forth conditions to be met  to be a withdrawal of the request for written recommendations.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
